Abstract: This document relates to non-human animal models (e.g., non-human mammalian models such as mouse models) for aging (e.g., neural aging). For example, non-human animal models having reduced or eliminated levels of aralkylamine N-acetyltransferase (AANAT) polypeptide expression are provided.

Abstract: Described are a system, method, and computer program product for detecting neurodegeneration using differential tractography and treating neurological disorders accordingly. The method includes obtaining a first diffusion magnetic resonance imaging (MRI) scan of the brain of the patient and obtaining a plurality of diffusion MRI scans of a group of other brains. The method also includes generating a control diffusion MRI scan based on the plurality of diffusion MRI scans of the group of other brains. The method further includes determining a first anisotropy of first neural tracks of the first diffusion MRI scan and a second anisotropy of second neural tracks of the control diffusion MRI scan. The method further includes determining a differential by comparing the first anisotropy to the second anisotropy and identifying at least one neurological disorder based on the differential and a location of the first neural tracks in the brain of the patient.

Abstract: The present disclosure relates to the use of a platelet inhibitor to prevent and/or treat aneurysms. The methods include prevention and/or treatment of aneurysms with the administration of a platelet inhibitor to a subject. The present disclosure further provides kits for performing such methods.

Abstract: Described are a system, method, and computer program product for detecting neurodegeneration using differential tractography and treating neurological disorders accordingly. The method includes obtaining a first diffusion magnetic resonance imaging (MRI) scan of the brain of the patient and obtaining a plurality of diffusion MRI scans of a group of other brains. The method also includes generating a control diffusion MRI scan based on the plurality of diffusion MRI scans of the group of other brains. The method further includes determining a first anisotropy of first neural tracks of the first diffusion MRI scan and a second anisotropy of second neural tracks of the control diffusion MRI scan. The method further includes determining a differential by comparing the first anisotropy to the second anisotropy and identifying at least one neurological disorder based on the differential and a location of the first neural tracks in the brain of the patient.